Skip to main content
SpringerLink
Log in

Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

MCF-7 cells growing in culture were used to study the mechanism of the antiproliferative activity of the antiprogestin mifepristone, as compared with the antiestrogen 4-hydroxytamoxifen or the combination of both. These steroid antagonists induced a significant time- and dose-dependent cell growth inhibition (cytotoxicity). This inhibition of cell survival was associated with a significant increase in DNA fragmentation (apoptosis), downregulation of bcl2, and induction of TGFβ1 protein. Abrogation of the mifepristone- and/or 4-hydroxytamoxifen-induced cytotoxicity by TGFβ1 neutralizing antibody confirms the correlation between induction of active TGFβ1 and subsequent cell death. The effect of a combination of mifepristone and 4-hydroxytamoxifen on cell growth inhibition, on the increase in DNA fragmentation, bcl2 downregulation, and induction of TGFβ1 protein was additive and significantly different (P < 0.05) from the effect of monotherapy. A translocation of protein kinase C (PKC) activity from the soluble to the particulate and/or nuclear fraction appeared to be also additive in cells treated with a combination of both 4-hydroxytamoxifen and mifepristone. These results suggest that the mechanism of the additive antiproliferative activity of mifepristone and tamoxifen could be explained at least in part by an additive induction of apoptosis in both estrogen and progesterone receptor positive MCF-7 breast cancer cells. A bcl2 downregulation, the PKC transduction pathway, and TGFβ1 expression seem to be involved in this additive mechanism of action. Our data further suggest that a combination of an antiprogestin with tamoxifen may be more effective than tamoxifen monotherapy in the management of human breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Michna H, Parczyk K: Differentiation and apoptosis as a therapeutic strategy for hormone-dependent cancers. In: Tenniswood M, Michna H (eds) Apoptosis in Hormone-Dependent Cancers. Springer-Verlag, Berlin, Heidelberg, 1995, pp 161–180

    Google Scholar 

  2. Schneider MR, Michna H, Nishino Y, El Etreby MF: Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT-mammary tumor model of the mouse and the DMBA-and the MNU-induced mammary tumor models of the rat. Eur J Cancer Clin Oncol 25/4: 691–701, 1989

    Google Scholar 

  3. Michna H, Schneider MR, Nishino Y, El Etreby MF: Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors; mechanistic studies. Breast Cancer Res Treat 14: 275–288, 1989

    Google Scholar 

  4. Michna H, Schneider MR, Nishino Y, El Etreby MF: The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem Molec Biol 34: 447–453, 1989

    Google Scholar 

  5. Schneider MR, Michna H, Nishino Y, El Etreby MF: Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Molec Biol 37: 783–787, 1990

    Google Scholar 

  6. Gill PG, Vignon F, Bardon S, Derocq D, Rochefort H: Difference between R 5020 and the antiprogestin RU 486 in antiproliferative effects on human breast cancer cells. Breast Cancer Res Treat 10: 37–45, 1987

    Google Scholar 

  7. Bardon S, Vignon F, Montcourrier P, Rochefort H: Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 47: 1441–1448, 1987

    Google Scholar 

  8. Kyprianou N, English HF, Davidson NE, Isaacs JT: Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51: 162–166, 1991

    Google Scholar 

  9. Waerri AM, Huovinen RL, Laine AM, Martikainen PM, Haerkoenen PL: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85: 1412–1418, 1993

    Google Scholar 

  10. Welsh JE: Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 72: 537–545, 1994

    Google Scholar 

  11. Nishino Y, Schneider MR, Michna H: Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI164.384. J Cancer Res Clin Oncol 120: 298–302, 1994

    Google Scholar 

  12. Klijn JGM, Setyono-Han B, Sander HJ, Lamberts SWJ, de-Jong FH, Deckers GH, Foekens JA: Preclinical and clinical treatment of breast cancer with antiprogestins. In: Beier HM, Spitz IM (eds) Progesterone Antagonists in Reproductive Medicine and Oncology. Oxford University Press, Cambridge, UK, 1994, pp 181–189

    Google Scholar 

  13. Sabourin JC, Martin A, Baruch J, Truc JB, Gompel A, Poitout P: Bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 59: 1–6, 1994

    Google Scholar 

  14. Leek RD, Kaklamanis L, Pezella F, Gatter KC, Harris AL: Bcl-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br J Cancer 69: 135–139, 1994

    Google Scholar 

  15. Gee JMW, Robertson JFR, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI: Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619–628, 1994

    Google Scholar 

  16. Wang TT, Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55: 2487–2489, 1995

    Google Scholar 

  17. Johnston SRD, MacLennan KA, Sacks NPM, Salter J, Smith IE, Dowsett M: Modulation of Bcl-2 and Ki-67 expression in estrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 30/11: 1663–1669, 1994

    Google Scholar 

  18. Hurlimann J, Larrinaga B, Vala D: Bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 426: 163–168, 1995

    Google Scholar 

  19. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, DiFronzo G, Rilke F, Veronesi U: The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499–504, 1994

    Google Scholar 

  20. Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, Pezzella F, Harris AL: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1: 189–198, 1995

    Google Scholar 

  21. Bhargava V, Kell DL, van de Rijn M, Warnke RA: Bcl-2 immunoreactivity in breast carcinoma correlated with hormone receptor positivity. Am J Pathol 145: 535–540, 1994

    Google Scholar 

  22. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK: Bcl2, p53, and response to tamoxifen in estrogen receptor positive metastatic breast cancer: A Southwest Oncology Group Study. J Clin Oncol 15: 1916–1922, 1997

    Google Scholar 

  23. Joensuu H, Pylkkanen L, Toikkanen S: Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145: 1191–1198, 1994

    Google Scholar 

  24. Copland JA, Hendry LB, Chu CK, Wood JC, Wrenn RW, Pantazis CG, Mahesh VB: Inhibition of estrogen stimulated mitogenesis by 3-phenylacetylamino-2,6-piperidinedione and its para-hydroxy analog. J Steroid Biochem Mol Biol 46(4): 451–462, 1993

    Google Scholar 

  25. Ojasoo T, Bignon E, Crastes de Paulet A, Dore JC, Gilbert J, Miquel JF, Pons M, Raynaud JP: Relative involvement of protein kinase C and of the estrogen receptor in the cytotoxic action of a population of triphenylethylenes on MCF7 cells as revealed by correspondence factorial (CF) analysis. J Steroid Biochem Mol Biol 44(3): 239–250, 1993

    Google Scholar 

  26. Colletta AA, Benson JR, Baum M: Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res Treat 31(1): 5–9, 1994

    Google Scholar 

  27. Rowlands MG, Budworth J, Jarman M, Hardcastle IR, McCague R, Gescher A: Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem Pharm 50(5): 723–726, 1995

    Google Scholar 

  28. Astruc ME, Chabret C, Bali P, Gagne D, Pons M: Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor. Endocrinology 136(3): 824–832, 1995

    Google Scholar 

  29. Gundimeda U, Chen ZH, Gopalakrishna R: Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 271(23): 13504–13514, 1996

    Google Scholar 

  30. Kiss Z, Anderson WH: Inhibition of phorbol ester-stimulated phospholipase D activity by chronic tamoxifen treatment in breast cancer cells. FEBS Lett 400(2): 145–148, 1997

    Google Scholar 

  31. Cabot MC, Zhang Z, Cao H, Iavie Y, Giuliano AE, Han TY, Jones RC: Tamoxifen activates cellular phospholipase C and D and clicits protein kinase C translocation. Int J Cancer 70(5): 567–574, 1997

    Google Scholar 

  32. Krasilnikov MA, Shatskaya VA, Kuzmino ZV, Barinov VV, Letyagin VP, Bassalyk LS: Regulation of phospholipid turnover by steroid hormones in endometrial carcinoma and breast cancer cells. Acta Endocrinol 128(6): 543–548, 1993

    Google Scholar 

  33. Lee SA, Karaszkiewicz JW, Anderson WB: Elevated levels of nuclear protein kinase C in multi-drug resistant MCF-7 human breast carcinoma cells. Cancer Res 52: 3750–3759, 1992

    Google Scholar 

  34. Guerrin M, Prats H, Mazars P, Valette A: Antiproliferative effects of phorbol esters on MCF-7 human breast adenocarcinoma cells: Relationship with enhanced expression of transforming growth factor β1. Biochim Biophys Acta 1137: 116–120, 1992

    Google Scholar 

  35. Rubenstein LV, Shoemaker RH, Paul KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR: Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113–1118, 1990

    Google Scholar 

  36. Hannan CJ, Liang Y, Allison JD, Searle JR: In vitro cytotoxicity against human cancer cell lines during pulsed magnetic field exposure. Anticancer Res 14: 1517–1520, 1994

    Google Scholar 

  37. Wooten MW, Wrenn RW: Redistribution of phospholipid/calcium-dependent protein kinase and altered phosphorylation of its soluble and particulate substrate proteins in phorbol ester-treated pancreatic acini. Cancer Res 45: 3912–3917, 1985

    Google Scholar 

  38. Wrenn RW, Herman LE: Integrin-linked tyrosine phosphorylation increases membrane association of protein kinase Cα in pancreatic acinar cells. Biochem Biophys Res Commun 208: 978–984, 1995

    Google Scholar 

  39. Schoenlein PV, Lewis J, Barrett JT, Wilson JD, Liang Y, El Etreby MF: Analysis of tamoxifen-induced chromosomal DNA fragmentation with pulsed field gel electrophoresis. Proceedings of the 88th Annual Meeting of the American Association for Cancer Research. April 12–16, 1997, San Diego, CA. Volume 38, March, 1997, Abstract 762

  40. Knowlton K, Mancini M, Creason S, Sedghinasab M, Hockenbery D, Anderson BO: Bcl2 slows in vitro breast cancer growth despite its antiapoptotic effect. Breast Cancer Res Treat 46: 70, 1997, Abstract 277

    Google Scholar 

  41. Teixeira C, Reed JC, Pratt MAC: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902–3907, 1995

    Google Scholar 

  42. Tonetti DA, Jordan VC: PKC isozyme expression in hormone-independent breast cancer. Breast Cancer Res Treat 46: 84, 1997, Abstract 349

    Google Scholar 

  43. Powell CT, Brittis NJ, Stec D, Hug H, Heston WDW, Fair WR: Persistent membrane translocation of protein kinase Cα during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ 7: 419–492, 1996

    Google Scholar 

  44. Trubiani O, Borgatti P, DiPrimio R: Protein kinase C modulation in apoptotic rat thymocytes: an ultrastructural analysis. Histochemistry 102: 311–316, 1994

    Google Scholar 

  45. Arteaga CL, Dugger TC, Moses HL, Hurd SD, Pietenpol JA: Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 4: 193–201, 1993

    Google Scholar 

  46. Koli KM, Ramsey TT, Ko Y, Dugger TC, Brattain MG, Arteaga CL: Blockade of transforming growth factor-beta signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells. J Biol Chem 272: 8296–8302, 1997

    Google Scholar 

  47. Perry RR, Kang Y, Greaves B: Relationship between tamoxifen-induced transforming growth factor β1 expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72: 1441–1446, 1995

    Google Scholar 

  48. Herman ME, Katzenellenbogen BS: Alteration of transforming growth factor-α and-β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54: 5867–5874, 1994

    Google Scholar 

  49. Dannecker C, Possinger K, Classen S: Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D. Ann Oncol 7: 391–395, 1996

    Google Scholar 

  50. Liang Y, Lewis J, Schoenlein P, Ogle T, Borke J, Sharawy M, Sherry R, El Etreby MF: Steroid receptor-mediated growth inhibitory activity of antiestrogens and antiprogestins in a hormone-responsive human breast cancer cell line. Proceedings of the 88th Annual Meeting of the American Association for Cancer Research, April 12–16, 1977, San Diego, Ca. Volume 38, March 1997, Abstract 3838

  51. Osborne CK, Boldt DD, Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 44: 1433–1439, 1984

    Google Scholar 

  52. Jeng MH, Langanfahey SM, Jordan VC: Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells. Endocrinology 132: 2622–2630, 1993

    Google Scholar 

  53. Cappelletti V, Miodini P, Fioravanti L, diFronzo G: Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines. Anticancer Res 15: 2551–2555, 1995

    Google Scholar 

  54. Savoldi G, Ferrari F, Ruggeri G, Sobek L, Albertini A, Di-Lorenzo D: Progesterone agonists and antagonists induce down-and up-regulation of estrogen receptors and estrogen inducible genes in human breast cancer cell lines. Intern J Biol Mark 10: 47–54, 1995

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Medical College of Georgia, Augusta, Georgia, USA

    M. Fathy El Etreby & Yayun Liang

  2. Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta, Georgia, USA

    Robert W. Wrenn & Patricia V. Schoenlein

Authors
  1. M. Fathy El Etreby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yayun Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert W. Wrenn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patricia V. Schoenlein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

El Etreby, M.F., Liang, Y., Wrenn, R.W. et al. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 51, 149–168 (1998). https://doi.org/10.1023/A:1006078032287

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006078032287

Search

Navigation